FIELD: biotechnology.
SUBSTANCE: invention relates to obtaining a trimer of the F protein of the respiratory syncytial virus (RSV), and can be used in medicine to induce an immune response to the RSV antigen. The F RSV protein is obtained recombinantly, containing a flexible linker instead of a protease cleavage site and mutations in the amino acid sequence, conferring greater stability to the protein in the “before fusion” conformation.
EFFECT: invention makes it possible to obtain a trimer of the F RSV protein, which is more stable in the “before fusion” conformation.
25 cl, 19 dwg, 4 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RSV F MUTANT PROTEIN AND ITS APPLICATION | 2020 |
|
RU2807742C1 |
| SELF-ASSEMBLED NANOSTRUCTURED VACCINES | 2019 |
|
RU2811439C2 |
| F RSV PROTEIN MUTANTS | 2016 |
|
RU2788403C2 |
| ANTIGENIC POLYPEPTIDES BASED ON THE RESPIRATORY SYNCYTIAL VIRUS SEQUENCE | 2019 |
|
RU2807992C2 |
| PROTEIN F RSV MUTANTS | 2016 |
|
RU2723039C2 |
| RSV PROTEINS IN PRE-CONFLUENCE CONFORMATION AND USE THEREOF | 2014 |
|
RU2761631C2 |
| IMMUNOGLOBULIN WITH ONE VARIABLE DOMAIN AGAINST RSV F-PROTEIN | 2016 |
|
RU2730671C2 |
| INFLUENZA HEMAGGLUTININ COMPOSITIONS WITH HETEROLOGOUS EPITOPES AND/OR ALTERED CLEAVAGE SITES DURING MATURATION | 2017 |
|
RU2769406C2 |
| ENGINEERED MULTI-SPECIFIC ANTIBODIES AND OTHER MULTIMERIC PROTEINS WITH ASYMMETRIC MUTATIONS IN THE CH2-CH3 REGION | 2018 |
|
RU2804031C2 |
| MULTIVALENT PD-L1-BINDING COMPOUNDS FOR TREATING MALIGNANT NEOPLASMS | 2020 |
|
RU2816646C2 |
